1. Home
  2. BRCB vs DMAC Comparison

BRCB vs DMAC Comparison

Compare BRCB & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BRCB

Black Rock Coffee Bar Inc. Class A Common Stock

N/A

Current Price

$24.33

Market Cap

448.5M

Sector

N/A

ML Signal

N/A

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$9.55

Market Cap

457.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRCB
DMAC
Founded
2008
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
448.5M
457.2M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
BRCB
DMAC
Price
$24.33
$9.55
Analyst Decision
Buy
Strong Buy
Analyst Count
6
4
Target Price
$28.40
$15.50
AVG Volume (30 Days)
361.2K
575.5K
Earning Date
11-11-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$189,494,000.00
N/A
Revenue This Year
$26.92
N/A
Revenue Next Year
$27.11
N/A
P/E Ratio
N/A
N/A
Revenue Growth
42.30
N/A
52 Week Low
$19.32
$3.19
52 Week High
$30.40
$10.42

Technical Indicators

Market Signals
Indicator
BRCB
DMAC
Relative Strength Index (RSI) N/A 71.27
Support Level N/A $7.76
Resistance Level N/A $10.42
Average True Range (ATR) 0.00 0.69
MACD 0.00 0.12
Stochastic Oscillator 0.00 76.95

Price Performance

Historical Comparison
BRCB
DMAC

About BRCB Black Rock Coffee Bar Inc. Class A Common Stock

Black Rock Coffee Bar Inc is a high-growth operator of guest-centric, drive-thru coffee bars offering premium caffeinated beverages and an elevated in-store experience crafted by its engaging baristas. It offers a broad range of premium coffee beverages, from its deliciously refreshing Nitro Cold Brew to its unapologetically indulgent Caramel Blondie. The company also offer competitively priced, premium classics, including the Americano and customizable Lattes, providing a high perceived value offering to its guests.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: